Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovary | 7 | 2016 | 258 | 3.160 |
Why?
|
| Doxorubicin | 6 | 2016 | 295 | 2.370 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2014 | 114 | 1.290 |
Why?
|
| Infertility, Female | 2 | 2021 | 93 | 1.170 |
Why?
|
| Dexrazoxane | 2 | 2015 | 2 | 1.070 |
Why?
|
| Antineoplastic Agents | 5 | 2015 | 2360 | 1.050 |
Why?
|
| Granulosa Cells | 4 | 2012 | 32 | 0.910 |
Why?
|
| Catechol O-Methyltransferase | 3 | 2007 | 68 | 0.870 |
Why?
|
| Fertilization in Vitro | 4 | 2021 | 55 | 0.820 |
Why?
|
| Pre-Eclampsia | 1 | 2021 | 246 | 0.640 |
Why?
|
| Fertility Preservation | 2 | 2015 | 18 | 0.640 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2007 | 214 | 0.620 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2014 | 20 | 0.600 |
Why?
|
| Culture Media | 1 | 2016 | 147 | 0.570 |
Why?
|
| Organ Culture Techniques | 1 | 2016 | 135 | 0.560 |
Why?
|
| Protective Agents | 1 | 2015 | 33 | 0.540 |
Why?
|
| Ovarian Follicle | 3 | 2014 | 72 | 0.520 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2015 | 27 | 0.520 |
Why?
|
| Callithrix | 1 | 2015 | 12 | 0.520 |
Why?
|
| Boronic Acids | 1 | 2014 | 55 | 0.500 |
Why?
|
| Reproductive Health Services | 1 | 2014 | 20 | 0.480 |
Why?
|
| Pyrazines | 1 | 2014 | 92 | 0.480 |
Why?
|
| Reproductive Health | 1 | 2014 | 32 | 0.480 |
Why?
|
| Estradiol | 3 | 2011 | 252 | 0.460 |
Why?
|
| Fertility | 4 | 2021 | 115 | 0.440 |
Why?
|
| Razoxane | 1 | 2012 | 3 | 0.430 |
Why?
|
| Guideline Adherence | 1 | 2014 | 224 | 0.430 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 275 | 0.430 |
Why?
|
| DNA Damage | 4 | 2015 | 366 | 0.430 |
Why?
|
| Menstrual Cycle | 2 | 2014 | 55 | 0.410 |
Why?
|
| Cell Proliferation | 2 | 2007 | 1579 | 0.400 |
Why?
|
| Female | 21 | 2021 | 44550 | 0.400 |
Why?
|
| Uterine Artery | 1 | 2011 | 3 | 0.400 |
Why?
|
| Pregnancy, Animal | 1 | 2011 | 58 | 0.390 |
Why?
|
| Retroviridae | 1 | 2011 | 79 | 0.380 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2011 | 90 | 0.380 |
Why?
|
| Uterus | 1 | 2011 | 215 | 0.350 |
Why?
|
| Endometrial Neoplasms | 2 | 2011 | 193 | 0.340 |
Why?
|
| Progesterone | 2 | 2015 | 110 | 0.340 |
Why?
|
| Phosphorylation | 3 | 2015 | 1106 | 0.300 |
Why?
|
| Endometrium | 1 | 2007 | 48 | 0.300 |
Why?
|
| Receptors, Progesterone | 1 | 2007 | 167 | 0.290 |
Why?
|
| Apoptosis | 4 | 2015 | 1683 | 0.290 |
Why?
|
| Animals | 10 | 2017 | 26590 | 0.270 |
Why?
|
| Litter Size | 2 | 2015 | 12 | 0.270 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2007 | 203 | 0.260 |
Why?
|
| Mice, Inbred Strains | 2 | 2015 | 307 | 0.230 |
Why?
|
| Pregnancy | 4 | 2021 | 2894 | 0.230 |
Why?
|
| Mice | 5 | 2015 | 11356 | 0.220 |
Why?
|
| Cells, Cultured | 5 | 2015 | 2819 | 0.210 |
Why?
|
| Models, Animal | 2 | 2015 | 263 | 0.210 |
Why?
|
| Placenta Accreta | 1 | 2021 | 6 | 0.210 |
Why?
|
| Embryo Transfer | 1 | 2021 | 29 | 0.200 |
Why?
|
| Cell Survival | 2 | 2016 | 969 | 0.200 |
Why?
|
| Humans | 15 | 2021 | 86678 | 0.190 |
Why?
|
| Infertility | 1 | 2021 | 37 | 0.190 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 1169 | 0.190 |
Why?
|
| Histones | 2 | 2012 | 311 | 0.180 |
Why?
|
| Telomere | 1 | 2021 | 108 | 0.180 |
Why?
|
| Cattle | 2 | 2017 | 376 | 0.170 |
Why?
|
| Ovarian Neoplasms | 2 | 2017 | 744 | 0.170 |
Why?
|
| Neoplasms | 1 | 2014 | 2898 | 0.170 |
Why?
|
| Blastocyst | 1 | 2017 | 34 | 0.150 |
Why?
|
| Second Harmonic Generation Microscopy | 1 | 2017 | 1 | 0.150 |
Why?
|
| Spermatozoa | 1 | 2017 | 62 | 0.150 |
Why?
|
| Bioreactors | 1 | 2016 | 10 | 0.140 |
Why?
|
| Embryonic Development | 1 | 2017 | 74 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1621 | 0.140 |
Why?
|
| Luteolysis | 1 | 2015 | 1 | 0.140 |
Why?
|
| Comet Assay | 1 | 2015 | 9 | 0.140 |
Why?
|
| Corpus Luteum | 1 | 2015 | 14 | 0.140 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 2015 | 4 | 0.140 |
Why?
|
| Dinoprost | 1 | 2015 | 26 | 0.140 |
Why?
|
| Prostaglandins | 1 | 2015 | 43 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 104 | 0.130 |
Why?
|
| Chemokines | 1 | 2015 | 73 | 0.130 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 232 | 0.130 |
Why?
|
| Caspase 9 | 1 | 2015 | 48 | 0.130 |
Why?
|
| Obesity | 1 | 2021 | 964 | 0.130 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 79 | 0.130 |
Why?
|
| Bortezomib | 1 | 2014 | 76 | 0.120 |
Why?
|
| Birth Weight | 1 | 2014 | 145 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 322 | 0.110 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 989 | 0.110 |
Why?
|
| Counseling | 1 | 2014 | 145 | 0.110 |
Why?
|
| Young Adult | 2 | 2015 | 5980 | 0.110 |
Why?
|
| Transcriptome | 1 | 2017 | 580 | 0.110 |
Why?
|
| Survivors | 1 | 2014 | 226 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2017 | 628 | 0.110 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2012 | 20 | 0.110 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2012 | 64 | 0.110 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2011 | 10 | 0.100 |
Why?
|
| Hydrogen Peroxide | 1 | 2012 | 158 | 0.100 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2011 | 31 | 0.100 |
Why?
|
| Spodoptera | 1 | 2011 | 32 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2015 | 8496 | 0.100 |
Why?
|
| Sheep | 1 | 2011 | 239 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1961 | 0.100 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 154 | 0.100 |
Why?
|
| Microtubules | 1 | 2011 | 119 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 133 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2011 | 168 | 0.090 |
Why?
|
| Estrogens | 1 | 2011 | 200 | 0.090 |
Why?
|
| Genetic Vectors | 1 | 2011 | 439 | 0.090 |
Why?
|
| Adult | 3 | 2015 | 25659 | 0.090 |
Why?
|
| United States | 1 | 2021 | 6681 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2012 | 448 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2011 | 429 | 0.080 |
Why?
|
| Dihydrotestosterone | 1 | 2007 | 27 | 0.080 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 1 | 2007 | 8 | 0.080 |
Why?
|
| Ovulation | 1 | 2007 | 68 | 0.080 |
Why?
|
| Carcinoma | 1 | 2011 | 436 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2014 | 2768 | 0.080 |
Why?
|
| Cell Line | 1 | 2012 | 2469 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 592 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2014 | 3613 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2007 | 270 | 0.070 |
Why?
|
| Tretinoin | 1 | 2007 | 126 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1981 | 0.070 |
Why?
|
| Steroids | 1 | 2007 | 177 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2007 | 143 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2007 | 1041 | 0.070 |
Why?
|
| Swine | 1 | 2007 | 555 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 639 | 0.060 |
Why?
|
| Time Factors | 1 | 2012 | 5214 | 0.060 |
Why?
|
| Child | 1 | 2014 | 6928 | 0.060 |
Why?
|
| Middle Aged | 2 | 2015 | 25040 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2015 | 7998 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 1197 | 0.050 |
Why?
|
| Adolescent | 1 | 2014 | 8984 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1749 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2021 | 464 | 0.040 |
Why?
|
| CpG Islands | 1 | 2017 | 151 | 0.040 |
Why?
|
| Risk Factors | 2 | 2021 | 5420 | 0.040 |
Why?
|
| Mutation | 1 | 2007 | 3968 | 0.040 |
Why?
|
| Epigenomics | 1 | 2017 | 100 | 0.040 |
Why?
|
| Oocytes | 1 | 2017 | 221 | 0.030 |
Why?
|
| Chemokine CXCL2 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Colforsin | 1 | 2015 | 74 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 1 | 2015 | 72 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2015 | 86 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 100 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 357 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1718 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 456 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 623 | 0.030 |
Why?
|
| DNA Adducts | 1 | 2011 | 21 | 0.030 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 48 | 0.020 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2011 | 34 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1384 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 79 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2011 | 224 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2706 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1921 | 0.020 |
Why?
|
| Male | 1 | 2017 | 40988 | 0.010 |
Why?
|